Summary:
Cara Therapeutics is a biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions.
Cara Therapeutics is a biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions.
Total raised: $15M
Investors 4
| Date | Name | Website |
| - | Connecticu... | ctinnovati... |
| - | Rho Ventur... | rhoventure... |
| - | Esperante | esperante.... |
| - | Rho Capita... | rho.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.07.2010 | Series D | $15M | - |
Mentions in press and media 14
| Date | Title | Description |
| 31.12.2024 | Houston's Health Tech Surge: A Year of Innovation and Growth | As 2024 draws to a close, Houston stands at the forefront of health tech innovation. The city has transformed into a bustling hub for life sciences, attracting talent, investment, and groundbreaking ideas. The landscape is vibrant, with sta... |
| 30.12.2024 | Top stories: Houston's most-read health tech news of 2024 | Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In the health tech category on InnovationMap, top stories included startup funding raised, IPO plans, FDA clearance,... |
| 30.12.2024 | Houston biotech biz to merge with public co., set local HQ | Houston-based Tvardi Therapeutics and Cara Therapeutics announced the companies have entered into a definitive merger agreement to combine in an all-stock transaction. Once completed, Houston will house the headquarters. Tvardi is a clinica... |
| 07.03.2024 | Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024 | - |
| 04.03.2024 | Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results | –Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline effic... |
| 02.11.2023 | Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty | - |
| 25.02.2022 | Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients | Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of chronic kidney disease associated-pruritus (CKD-aP) in hemodialysis patients European Com... |
| 03.01.2018 | Centrexion’s $67M Series D round to fund Phase 3 pain studies | Despite being just four years old, Centrexion is building a significant pipeline of non-opioid, non-steroidal pain medications. CNTX-4975 is being developed to treat pain from osteoarthritis and Morton’s Neuroma. The drug is a synthetic tra... |
| 30.06.2017 | Cara Therapeutics: A lesson in clinical trial failure and spin | Cara Therapeutics tried to misdirect investors away from the failure of its osteoarthritis pain pill by burying negative results from a mid-stage clinical trial in the middle of a press release issued Thursday night. The ploy didn’t work. C... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
Show more